Full Text

chemotherapy in advanced head and neck cancer[notdef]

[notdef]

[notdef]ClinicalM Tsukuda*,1, A Kida2, M Fujii3, N Kono4, T Yoshihara5, Y Hasegawa6, M Sugita7 and Chemotherapy Study

Group of Head and Neck Cancer1Department of Biology and Function in the Head and Neck, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan;2Department of Otorhinolaryngology Head and Neck Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan; 3Division of Hearing and

Balance Research, National Institute of Sensory Organs, National Tokyo Medical Center, Meguro-ku, Tokyo, Japan;4Department of Otorhinolaryngology Studies6Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya, Japan; 7Department

of Environmental and Occupational Health, Toho University School of Medicine, Ota-ku, Tokyo, JapanHead and Neck Surgery, Kyorin University School of Medicine, Mitaka-City, Tokyo, Japan;5Department of Otolaryngology, Tokyo Womens Medical

University, Shinjyuku-ku, Tokyo, Japan;The purpose of this study was to determine the feasible adjuvant therapy administration schedule of S-1 for locoregionally advanced

squamous cell carcinoma of the head and neck (SCCHN). Patients receiving definitive treatments were randomly assigned to either

arm A (51 cases) receiving oral S-1 of 2-week administration followed by 1-week rest for 6 months, or arm B receiving S-1 of 4-week

administration followed by 2-week rest for 6 months. Planned treatment was given in 40% of patients in arm A and 29% in arm B. The

cumulative rates of the relative total administration dose of S-1 at 100% were 54.9% (95% CI: 40.169.7%) in arm A and 34.3% (95%

CI: 21.147.4%) in arm B, respectively (P 0.054). Adverse events were recorded in 41 patients (82.0%) in arm A and 48 patients(94.1%) in arm B (P 0.060). The incidences of diarrhoea (10 vs 28%; Po0.05) and skin toxicities (18 vs 37%; Po0.05) were

significantly higher in arm B. One-year disease-free survival was similar in both arms: arm A 81.2% (95% CI:...

Show less

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

Full Text

Suggested sources

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

Content area

Full Text

Suggested sources